API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

12 clusters · 71 sources · 59 days · First seen · Last updated

Indian Supreme Court litigation over medicine pricing

Overview

Advocate Ashwini Upadhyay filed a Public Interest Litigation (PIL) in the Supreme Court of India seeking a uniform national framework to address the manufacture and sale of counterfeit and adulterated medicines. The petition, prompted by reports of a racket in Karnataka involving fake cancer drugs and critical-care injections, called for stricter penalties, including the confiscation of assets from manufacturers and financiers. Subsequently, the Supreme Court declined to adjudicate the petition, instead forwarding it to the government as a representation for consideration. The Supreme Court has since shifted focus toward pharmaceutical pricing disparities. A bench expressed severe concern over the massive gap between supply prices and maximum retail prices (MRP), describing the situation as ‘carnage’. The court highlighted instances where cancer drugs supplied to retailers for approximately Rs 2,700 carried an MRP of Rs 27,000, and flagged practices by corporate hospitals that mandate the use of in-house pharmacies. In response, the National Pharmaceutical Pricing Authority (NPPA) implemented a Trade Margin Rationalisation (TMR) measure to cap margins at 30% for 137 non-scheduled anti-cancer drugs. As of November 9, 2026, revised prices for 1,364 anti-cancer drug formulations have come into effect. Following the implementation, 85 pharmaceutical companies reported revised MRPs covering 121 drugs. Of these, 679 brands reported price reductions exceeding 50 percent, with the highest reduction reaching 96.45 percent. For instance, the breast cancer treatment capsule ‘Palpro’ reportedly dropped from Rs 40,421.33 to Rs 2,720. The Ministry of Chemicals and Fertilizers estimates these reductions will save consumers approximately Rs 3,540.38 crore annually. To ensure compliance, the NPPA has ordered strict monitoring of the trade margin rationalisation for these 137 drugs. Manufacturers, stockists, and medical institutions must prominently display updated price lists.

Entities

National Pharmaceutical Pricing Authority · India · Department of Pharmaceuticals · Supreme Court of India · Ministry of Chemicals and Fertilizers

Claims

What the coverage asserts, and how many sources carry each claim.

Timeline

  1. [BUSINESS] 7 sources
    India NPPA mandates strict monitoring of 137 anti-cancer drug prices

    India's NPPA has ordered strict monitoring of 137 anti-cancer drugs following a 30 per cent cap on trade margins to ensure lower prices are passed to patients.

  2. [HEALTH] 2 sources
    India implements major price cuts for cancer medications

    India has slashed the cost of nearly 1,300 cancer drug brands by up to 96 percent, a reform expected to save patients approximately 2.59 billion euros annually.

  3. [HEALTH] 11 sources
    India implements price cuts for 1,364 anti-cancer drugs

    India has slashed prices for 1,364 anti-cancer drugs by up to 96.45 percent, aiming to save consumers Rs 3,540 crore annually through capped trade margins.

  4. [HEALTH] 13 sources
    India caps trade margins on 137 anti-cancer drugs to reduce costs

    India's NPPA has capped trade margins on 137 anti-cancer drugs, effective November 9, aiming to save patients approximately Rs 3,502 crore annually through significant price reductions.

  5. [BUSINESS] 5 sources
    NPPA revises prices for 543 brands of anti-cancer drugs in India

    India's NPPA has revised prices for 543 anti-cancer drug brands, effective November 9, 2026, capping trade margins for 137 non-scheduled medicines to improve patient affordability.

  6. [BUSINESS] 25 sources
    India NPPA revises prices for 543 anti-cancer drug brands

    India's NPPA has slashed prices for 543 anti-cancer drug brands by up to 93.3% following a trade margin cap. The new rates take effect November 9, 2026, though many patented drugs remain unchanged.

  7. [HEALTH] 6 sources
    India proposes 30% trade margin cap on cancer drugs

    The Indian government proposes capping trade margins on non-scheduled cancer drugs at 30% of MRP to curb excessive hospital mark-ups and save patients an estimated ₹2,500 crore annually.

  8. [HEALTH] 2 sources
    India to reduce prices of 137 cancer medicines by up to 70%

    India will slash prices of 137 cancer medicines by up to 70% starting November 9, 2026, after the NPPA capped trade margins at 30% to improve treatment accessibility.

  9. [HEALTH] 13 sources
    NPPA caps trade margins on 137 anti-cancer drugs in India

    India's NPPA has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, potentially reducing prices by up to 70% starting November 9, 2026, to improve treatment affordability.

  10. [POLITICS] 9 sources
    India to cap trade margins on cancer drugs amid Supreme Court scrutiny

    The Indian government will cap trade margins on certain cancer drugs at 30% of MRP, though the Supreme Court has urged a broader review of excessive markups on all medicines and medical devices.

  11. [POLITICS] 14 sources
    Supreme Court slams massive markups on cancer drugs

    The Supreme Court of India has slammed the massive markups on cancer drugs, calling the price disparity ‘carnage’ and questioning the need for a uniform 16% margin cap on all medicines.

  12. [HEALTH] 4 sources
    Supreme Court PIL seeks national framework to combat fake medicines

    A PIL in the Indian Supreme Court seeks a national framework to tackle fake and adulterated medicines, demanding time-bound trials and asset confiscation following reports of counterfeit drug rackets.

Sources

aajtak.com · agniban.com · avnews.in · bhaskarhindi.com · bhaskarlive.in · bilkulonline.com · cargoinsights.co · chennaionline.com · chennaivision.com · cinemaskope.com.br · deccanchronicle.com · desitalkchicago.com · devdiscourse.com · disabledperson.com · dtnext.in · ehealth.eletsonline.com · en.etemaaddaily.com · english.mathrubhumi.com · english.publictv.in · expresspharma.in · freshheadline.com · highlandpost.com · hindi.asianetnews.com · india.com · kannada.asianetnews.com · khabarpahad.com · kreiszeitung.de · kurierverlag.de · lagatar24.com · lawchakra.in · madhyamamonline.com · malaimurasu.com · medgatetoday.com · medicaldialogues.in · millenniumpost.in · montagehotels.com · morungexpress.com · mpbreakingnews.in · navabharat.com · navbharatlive.com · newindianexpress.com · news.abplive.com · news18.com · news9live.com · newsable.asianetnews.com · newsindialive.in · newstodaynet.com · newswire.lk

This summary has been updated 22 times: see revision history